Recently, a leading company in the North China Stock Exchange's recombinant collagen sector has emerged.Jinbo BioAnnouncing Executive Leadership Changes: Official Statement on Major Management RestructuringCompany founder and Chairman Yang Xia will no longer concurrently serve as General Manager.with nearly three decades of experience managing the full pharmaceutical and healthcare industry chainGao Song, former CEO of iKang Holdings, appointed as General ManagerThis personnel appointment takes effect as of the date of this announcement and remains valid until the current term of the Board of Directors expires.

This departure as General Manager does not mean leaving the company's core management team. The announcement clarifies that Yang Xia will continue to serve as Chairman of the Board, retaining her roles on the Board's Strategy and Sustainability Committee, Nominating Committee, and Compensation and Assessment Committee, while stepping down from day-to-day operational management responsibilities.Refocus on top-level strategic planning, cutting-edge technology R&D, and industry-academia-research innovation.。

Shang Gao, who has succeeded as General Manager, has long been deeply engaged in the pharmaceutical and healthcare sector.Holds a Master's degree from the School of Life Sciences at Fudan University and an MBA from CEIBS. Spent 22 years early in his career at GlaxoSmithKline China, where he held key roles including Director of Hepatitis Sales, Head of Commercial Excellence, and Vice President & Head of Respiratory Business Unit. He is an expert in standardized operations for multinational pharmaceutical companies, building national sales systems, distributor management, and compliant operations, with extensive experience in commercializing aesthetics, prescription drugs, and medical devices.

2019年起，高嵩深耕本土医疗龙头企业，任职艾迪康近7年，历任商务运营副总裁、集团CEO，主导企业规模化扩张、组织架构升级与多业务协同发展，具备大型医疗集团精细化操盘、终端渠道深度渗透的成熟能力。

The recombinant collagen sector is moving past the era of unregulated growth and enteringTechnology, Channels, Branda stage of comprehensive competition. This personnel iteration represents a significant upgrade to Biomere's governance structure and signals that the company will continue to lead the fiercely competitive industry by leveraging its dual advantages of "core technology + professional operations." The pace of its channel expansion and the commercialization results of new products are worth close monitoring by the industry in the future.

2026 (2nd) EMBC Bio-Manufacturing Industry Conference & Exhibition (Summer)

2026 (2nd) EMBC Bio-Manufacturing Industry Conference & Exhibition (Summer)will be8 27-28Held in Shanghai, the exhibition will invite2000+ Attendees,100+Speaker,20+Premium exhibitors, featuring "Exhibitions - Conferences - Meetings - EventsFour core modules focused on "breakthroughs in fundamental research + cross-domain industrial implementation."

Exhibition FocusMedical Aesthetics, Bio-based Materials & Green Chemicals, Food, Agriculture, and AI EmpowermentExhibitor recruitment is now open. Contact us for details on participating in the exhibition.